These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 38724203)

  • 1. T2-FLAIR Mismatch: An Imaging Biomarker for Children's
    van Maren EA; Dankbaar JW; Wesseling P; Plasschaert S; Muhlebner A; Hoving EW; Robe PA; Snijders TJ; Hoogendijk R; Kranendonk MEG; Lequin MH
    AJNR Am J Neuroradiol; 2024 Jun; 45(6):747-752. PubMed ID: 38724203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathological analysis of T2-FLAIR mismatch sign in lower-grade gliomas.
    Deguchi S; Oishi T; Mitsuya K; Kakuda Y; Endo M; Sugino T; Hayashi N
    Sci Rep; 2020 Jun; 10(1):10113. PubMed ID: 32572107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantification of T2-FLAIR Mismatch in Nonenhancing Diffuse Gliomas Using Digital Subtraction.
    Cho NS; Sanvito F; Le VL; Oshima S; Teraishi A; Yao J; Telesca D; Raymond C; Pope WB; Nghiemphu PL; Lai A; Cloughesy TF; Salamon N; Ellingson BM
    AJNR Am J Neuroradiol; 2024 Feb; 45(2):188-197. PubMed ID: 38238098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T2-FLAIR Mismatch Sign in Pediatric Low-Grade Glioma.
    Wagner MW; Nobre L; Namdar K; Khalvati F; Tabori U; Hawkins C; Ertl-Wagner BB
    AJNR Am J Neuroradiol; 2023 Jul; 44(7):841-845. PubMed ID: 37348970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Super T2-FLAIR mismatch sign: a prognostic imaging biomarker for non-enhancing astrocytoma, IDH-mutant.
    Ozono I; Onishi S; Yonezawa U; Taguchi A; Khairunnisa NI; Amatya VJ; Yamasaki F; Takeshima Y; Horie N
    J Neurooncol; 2024 Sep; 169(3):571-579. PubMed ID: 38995493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isomorphic diffuse glioma is a morphologically and molecularly distinct tumour entity with recurrent gene fusions of MYBL1 or MYB and a benign disease course.
    Wefers AK; Stichel D; Schrimpf D; Coras R; Pages M; Tauziède-Espariat A; Varlet P; Schwarz D; Söylemezoglu F; Pohl U; Pimentel J; Meyer J; Hewer E; Japp A; Joshi A; Reuss DE; Reinhardt A; Sievers P; Casalini MB; Ebrahimi A; Huang K; Koelsche C; Low HL; Rebelo O; Marnoto D; Becker AJ; Staszewski O; Mittelbronn M; Hasselblatt M; Schittenhelm J; Cheesman E; de Oliveira RS; Queiroz RGP; Valera ET; Hans VH; Korshunov A; Olar A; Ligon KL; Pfister SM; Jaunmuktane Z; Brandner S; Tatevossian RG; Ellison DW; Jacques TS; Honavar M; Aronica E; Thom M; Sahm F; von Deimling A; Jones DTW; Blumcke I; Capper D
    Acta Neuropathol; 2020 Jan; 139(1):193-209. PubMed ID: 31563982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The reliability and interobserver reproducibility of T2/FLAIR mismatch in the diagnosis of IDH-mutant astrocytomas.
    Yeniçeri İÖ; Yıldız ME; Özduman K; Danyeli AE; Pamir MN; Dinçer A
    Diagn Interv Radiol; 2021 Nov; 27(6):796-801. PubMed ID: 34792037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T2-FLAIR mismatch sign, an imaging biomarker for CDKN2A-intact in non-enhancing astrocytoma, IDH-mutant.
    Onishi S; Kojima M; Yamasaki F; Amatya VJ; Yonezawa U; Taguchi A; Ozono I; Go Y; Takeshima Y; Hiyama E; Horie N
    Neurosurg Rev; 2024 Aug; 47(1):412. PubMed ID: 39117984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancing glioma care with advanced imaging: T2-FLAIR mismatch as a predictive biomarker in IDH-mutant astrocytoma.
    Nadeem M; Shahzad UB; Tahir N; Areej A
    Neurosurg Rev; 2024 Aug; 47(1):512. PubMed ID: 39212803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The T2-FLAIR-mismatch sign as an imaging biomarker for IDH and 1p/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance.
    Goyal A; Yolcu YU; Goyal A; Kerezoudis P; Brown DA; Graffeo CS; Goncalves S; Burns TC; Parney IF
    Neurosurg Focus; 2019 Dec; 47(6):E13. PubMed ID: 31786548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical significance of the T2-FLAIR mismatch sign in grade II and III gliomas: a population-based study.
    Corell A; Ferreyra Vega S; Hoefling N; Carstam L; Smits A; Olsson Bontell T; Björkman-Burtscher IM; Carén H; Jakola AS
    BMC Cancer; 2020 May; 20(1):450. PubMed ID: 32434559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pediatric-type diffuse low-grade glioma with T2-FLAIR mismatch sign: a case report and literature review.
    Hwa JC; Wong AM; Jung SM; Wu CT
    Childs Nerv Syst; 2024 Aug; 40(8):2271-2278. PubMed ID: 38884778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The T2-FLAIR mismatch sign as an imaging marker for non-enhancing IDH-mutant, 1p/19q-intact lower-grade glioma: a validation study.
    Broen MPG; Smits M; Wijnenga MMJ; Dubbink HJ; Anten MHME; Schijns OEMG; Beckervordersandforth J; Postma AA; van den Bent MJ
    Neuro Oncol; 2018 Sep; 20(10):1393-1399. PubMed ID: 29590424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Histopathologic and Radiologic Features of T2-FLAIR Mismatch Sign in IDH-Mutant 1p/19q Non-codeleted Astrocytomas.
    Fujita Y; Nagashima H; Tanaka K; Hashiguchi M; Hirose T; Itoh T; Sasayama T
    World Neurosurg; 2021 May; 149():e253-e260. PubMed ID: 33610870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MYB/MYBL1-altered gliomas frequently harbor truncations and non-productive fusions in the MYB and MYBL1 genes.
    Chung HJ; Rajan S; Wu Z; Ferrone CK; Raffeld M; Lee I; Gagan J; Dampier C; Abdullaev Z; Tyagi M; Cimino PJ; Quezado M; Aldape K
    Acta Neuropathol; 2024 Oct; 148(1):54. PubMed ID: 39422766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of diagnostic performance of radiologist- and AI-based assessments of T2-FLAIR mismatch sign and quantitative assessment using synthetic MRI in the differential diagnosis between astrocytoma, IDH-mutant and oligodendroglioma, IDH-mutant and 1p/19q-codeleted.
    Kikuchi K; Togao O; Yamashita K; Momosaka D; Kikuchi Y; Kuga D; Yuhei S; Fujioka Y; Narutomi F; Obara M; Yoshimoto K; Ishigami K
    Neuroradiology; 2024 Mar; 66(3):333-341. PubMed ID: 38224343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiographic assessment of contrast enhancement and T2/FLAIR mismatch sign in lower grade gliomas: correlation with molecular groups.
    Juratli TA; Tummala SS; Riedl A; Daubner D; Hennig S; Penson T; Zolal A; Thiede C; Schackert G; Krex D; Miller JJ; Cahill DP
    J Neurooncol; 2019 Jan; 141(2):327-335. PubMed ID: 30536195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of partial T2-FLAIR mismatch sign and isocitrate dehydrogenase mutation in WHO grade 4 gliomas: results from the ReSPOND consortium.
    Lee MD; Patel SH; Mohan S; Akbari H; Bakas S; Nasrallah MP; Calabrese E; Rudie J; Villanueva-Meyer J; LaMontagne P; Marcus DS; Colen RR; Balana C; Choi YS; Badve C; Barnholtz-Sloan JS; Sloan AE; Booth TC; Palmer JD; Dicker AP; Flanders AE; Shi W; Griffith B; Poisson LM; Chakravarti A; Mahajan A; Chang S; Orringer D; Davatzikos C; Jain R;
    Neuroradiology; 2023 Sep; 65(9):1343-1352. PubMed ID: 37468750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advanced imaging parameters improve the prediction of diffuse lower-grade gliomas subtype, IDH mutant with no 1p19q codeletion: added value to the T2/FLAIR mismatch sign.
    Lee MK; Park JE; Jo Y; Park SY; Kim SJ; Kim HS
    Eur Radiol; 2020 Feb; 30(2):844-854. PubMed ID: 31446467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T2-FLAIR Mismatch Sign Predicts DNA Methylation Subclass and CDKN2A/B Status in IDH-Mutant Astrocytomas.
    Lee MD; Jain R; Galbraith K; Chen A; Lieberman E; Patel SH; Placantonakis DG; Zagzag D; Barbaro M; Guillermo Prieto Eibl MDP; Golfinos JG; Orringer DA; Snuderl M
    Clin Cancer Res; 2024 Aug; 30(16):3512-3519. PubMed ID: 38829583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.